정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
2186 | Completed | Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early | Corona Virus Infection | Drug: Clarithromycin | Phase 2 | Hellenic Institute for the Study of Sepsis | OTHER | 90 | All | 18 Years | COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi, Athens, Greece 2nd Department of Internal Medicine, General Hospital of Nikaia, Piraeus, Attica, Greece 2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece 1st University Department of Internal Medicine, LAIKO General Hospital of Athens, Athens, Greece 2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece 3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece 1st Department of Internal Medicine, General University Hospital of Ioannina, Ioannina, Greece 2nd Department of Internal Medicine, General Hospital of Piraeus "Tzaneio", Piraeus, Greece 1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloniki, Greece |
2185 | Recruiting | Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19 | Hematological Malignancy | Drug: BMS-986253 | Phase 2 | Matthew Dallos, Bristol-Myers Squibb | OTHER | 138 | All | 18 Years | Columbia University Irving Medical Center, New York, New York, United States |
2184 | Completed | Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19 | Oxidative Stress | Drug: Vitamin C Drug: Vitamin E Drug: Melatonin Drug: N-acetyl cysteine Drug: Pentoxifylline |
Not Applicable | Unidad Temporal COVID-19 en Centro Citibanamex, Instituto Nacional de Cardiologia Ignacio Chavez, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | OTHER | 110 | All | Unidad Temporal COVID-19 en Centro Citibanamex, Mexico City, Mexico | |
2183 | Active, not recruiting | Anti-SARS Cov-2 T Cell Infusions for COVID 19 | COVID 19 | Biological: Dose Finding Phase (MTD) Biological: Partially HLA-matched SARS-CoVSTs Other: Routine care (no SARS-CoVSTs) |
Phase 1 | Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute, AlloVir | OTHER | 58 | All | 18 Years | Houston Methodist Hospital, Houston, Texas, United States |
2182 | Active, not recruiting | Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19 | Covid19 | Drug: ISIS 721744 Drug: Normal Saline |
Phase 2 | Hospital do Coracao, Ionis Pharmaceuticals, Inc., Hospital Moinhos de Vento | OTHER | 111 | All | 18 Years ~ 80 Years | Hospital Naval Marcilio Dias, Rio De Janeiro, Brazil BP-A Beneficiencia Portuguesa de Sao Paulo, Sao Paulo, Brazil Hospital Sao Paulo - UNIFESP, Sao Paulo, Brazil |
2181 | Completed | Antiseptic Mouth Rinses to Reduce Salivary Viral Load in COVID-19 Patients | Covid19 | Drug: Betadineⓒ bucal 100 mg/ml Drug: Oximen® 3% Drug: Clorhexidine Dental PHBⓒ Drug: Vitis Xtra Forteⓒ Drug: Distilled Water |
Not Applicable | Fundacion para el Fomento de la Investigacion Sanitaria y Biomedica de la Comunitat Valenciana, Hospital Universitario Fundacion Jimenez Diaz, Hospital Universitario General de Villalba, Hospital Universitario Infanta Elena, Hospital Universitario Virgen de la Arrixaca, Hospital Clinico Universitario de Valencia, Dentaid SL | OTHER | 160 | All | 18 Years | Alejandro Mira, Valencia, Spain |
2180 | Recruiting | Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19) | Pharyngeal Diseases | Drug: Oral-B Mouth Sore mouthwash Drug: Crest Pro-Health Multi-Protection mouthwash Drug: CloSYS Ultra Sensitive Rinse mouthwash Drug: Distilled water Drug: Listerine Zero Mouthwash Product |
Phase 2 | University of California, San Francisco, Rowpar Pharmaceuticals, Inc. | OTHER | 150 | All | 18 Years | University Of California, San Francisco, San Francisco, California, United States |